Video
— Our panel of experts discuss how they monitor patients on biologics and JAK inhibitors
Latest in Video
Peter Lio, MD, says he can't wait to have more flexibility for his pediatric patients
Steven Feldman, MD, PhD, highlights the importance of improving quality of life
Our panel of experts discuss the appropriate time to introduce systemic therapy or switch agents
Our understanding of eczema's potential comorbidities will likely expand, says Lakshi Aldredge
Our panel of experts discuss the appropriate time to introduce systemic therapy or switch agents
Our understanding of eczema's potential comorbidities will likely expand, says Lakshi Aldredge
More in Video
We've got great treatments, says Steven Feldman, the key is getting patients to use them
Our panel of experts discuss the "explosion" in new systemic and topical agents
James Del Rosso, DO, says to keep an open mind when determining the best option for patients
Will be good news for patients when drug is approved, says Emma Guttman-Yassky, MD, PhD
Peter Lio, MD, discusses how he approaches that decision-making discussion
Roy Herbst, MD, PhD, leads a discussion on ADCs targeting TROP2, HER2, and HER3
Roy Herbst, MD, PhD, leads a discussion on current and emerging treatments available
Roy Herbst, MD, PhD, leads a discussion on the newest targeted and immunotherapies
Roy Herbst, MD, PhD, leads a discussion on new data coming down the pike
Results may lead to an alternative to JAK inhibitors
Additional screening recommended after diagnosis of either disease, researcher says
Failure of one JAK inhibitor doesn't necessarily mean failure of another, says Brittany Craiglow
With new therapies here and on the way, clinician choice comes down to comfort, says Brett King
"Because it's psychiatry, testing has not been more widely adopted," says Benjamin Cheyette
